- Home
- GLYC
GLYC
GlycoMimetics Inc.
as 07-26-2024 4:00pm EST
GlycoMimetics Inc is a clinical-stage biotechnology company. It is focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using expertise in carbohydrate chemistry and knowledge of carbohydrate biology, the company is developing a pipeline of proprietary glycomimetics that may inhibit disease-related functions of carbohydrates, such as the roles it play in inflammation, cancer, and infection.
Upcoming Earnings Alert:
Get ready for potential market movements as GlycoMimetics Inc. GLYC prepares to release earnings report on 31 Jul 2024.
| Founded: | 2003 | Country: | United States |
| Employees: | N/A | City: | ROCKVILLE |
| Market Cap: | 17.6M | IPO Year: | 2014 |
| Target Price: | $12.00 | AVG Volume (30 days): | 1.4M |
| Analyst Decision: | Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.58 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.20 - $3.53 | Next Earning Date: | 07-31-2024 |
| Revenue: | $10,000 | Revenue Growth: | -86.67% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of GlycoMimetics Inc. (GLYC)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Rock Edwin | GLYC | Chief Medical Officer | Jun 20 '24 | Buy | $0.27 | 115,000 | $30,716.50 | 680,403 | SEC Form 4 |
| Rock Edwin | GLYC | Chief Medical Officer | Jun 20 '24 | Buy | $0.25 | 190,000 | $48,108.00 | 565,403 | SEC Form 4 |
| Hahn Brian M. | GLYC | SVP Finance, CFO | Jun 18 '24 | Buy | $0.25 | 17,500 | $4,334.75 | 70,643 | SEC Form 4 |
Latest GlycoMimetics Inc. News
GLYC Breaking Stock News: Dive into GLYC Ticker-Specific Updates for Smart Investing
Business Wire
2 days ago
GlycoMimetics Announces Strategic Review and Corporate Restructuring Plan
Simply Wall St.
a month ago
Senior VP & Chief Medical Officer of GlycoMimetics Edwin Rock Buys 81% More Shares
Business Wire
2 months ago
GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
Business Wire
2 months ago
GlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024
Clinical Trials Arena
2 months ago
Pipeline Moves: Phase III AML trial fails to meet primary endpoint
Associated Press Finance
3 months ago
GlycoMimetics: Q1 Earnings Snapshot
Clinical Trials Arena
3 months ago
Uproleselan’s failed Phase III AML trial shakes up GlycoMimetics’ future
Clinical Trials Arena
3 months ago
GlycoMimetics reports data from Phase III AML treatment trial
Compare GLYC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GLYC GlycoMimetics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.